News

B.C. funds new cancer treatment test

By The Canadian Press

VANCOUVER - B.C. has become the latest province to fund a test that can help determine whether patients with a certain type of early stage breast cancer could benefit from chemotherapy.

California-based Genomic Health says the BC Cancer Agency has agreed to fund the company's Oncotype DX test.

The test, which costs US$4,300, examines genes within breast cancer tumours to predict which patients would benefit from chemotherapy.

Conversely, the test is also used to predict which patients would see little or no benefit from chemotherapy.

The funding applies to patients that meet a list of criteria, including that they have early stage, node-negative, estrogen receptor-positive invasive breast cancer.

The test is already funded by provincial governments in Alberta, Ontario, Quebec, Saskatchewan, and Newfoundland and Labrador.

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Postcards from the edge of history
 
Looking Back November 19
 
After the vote: Newly elected councillors respond
Hupacasath raises flag
 
A Green Party in Parksville
 
Order dissolves over lack of membership
Station: Ticket to rock
 
Quinn-tessential Bachand
 
The Week — Nov. 10

Community Events, November 2014

Add an Event


Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Nov 19 edition online now. Browse the archives.